An interesting excerpt from the PDF:
The evolution of treatment programs through incremental addition of tumor-specific frequencies is illustrated by
the case of a 51 year old woman with ovarian cancer. This patient was diagnosed with FIGO stage III (G2-G3)
ovarian cancer in October 1997 and had received multiple courses of palliative chemotherapy until 2005. As
seen on Figure 2, the initial treatment consisting of 15 frequencies did not yield any response. Upon reexamination,
11 additional frequencies (total of 26) were added to the treatment program in August 05.
Because of disease progression, treatment with single agent bevacizumab was initiated in November 05.
Interestingly, the CA 125 level had decreased by 200 units between October and November 2005, prior to the
initiation of bevacizumab. Combined treatment with amplitude-modulated electromagnetic fields and
bevacizumab resulted in a decrease in CA 125 level from 2140 to 540 in May 06. Treatment was
supplemented with cyclophosphamide from March to September 07. The patient was hospitalized with
pneumonia and elected to only receive amplitude-modulated electromagnetic fields since September 07. As of
April 1, 2009 the patient has stable disease and is asymptomatic. She has been receiving experimental
treatment without interruption for a total of +50.5 months.
|